Compositions comprising hmg-coa reductase inhibitor
CA 2493761 A1 · Owner: Novartis Ag · Inventors: Meyer, Andreas; Ogorka, Joerg; Desset-Brethes, Sabine
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to pharmaceutical compositions for sustained release comprising as active ingredient an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof said composition comprising an inner , phase (internal) and an outer phase (external) wherein at least the outer , phase comprises at least one matrix former.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 24, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 24, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 24, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.